Preliminary in Medical Technology

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhib...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

SAN MATEO, Calif., July 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ) announced today the preliminary results of a short-term clinical study (Study C123) of Qutenza(TM) in patients with postherpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anestheti...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...

TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009. (Logo: http://www.newscom....

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

Results show improved insulin sensitivity and lower glucose levels without the side effects of current therapies KALAMAZOO, Mich., May 14 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) announced today that its lead compound, MSDC-0160, can improve insulin sensitivity and lo...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Cal...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P)...

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

-Cohort 1 Data Promising for Type 2 Diabetes- PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Ge...

Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the tri...

Neuronetrix Announces Preliminary Alzheimer's Study Results at the Society for Neuroscience Conference

LOUISVILLE, Ky., Dec. 8 /PRNewswire/ -- Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION(TM) System to diagnose Alzheimer's disease. The study was performed with Alzheimer's patients at the ...

CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma

- Data presented at the 2008 iSBTc Annual Meeting - - Conference call to be hosted today at 11:00 a.m. ET to discuss results - BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) announced today preliminary data from an ongoing Phase II trial of CR011-vcMM...

What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study

BOSTON, Sept. 13 /PRNewswire-USNewswire/ -- Cardiovascular disease kills more women each year than all cancers combined. Although this statistic is gaining more recognition among physicians and patients, the unique risk factors and symptoms of female patients make diagnosis and prognosis of wo...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

- 88% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1000mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys plus Copegus - PRINCETON, N.J., Aug. 5 /PRNewswir...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...

Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are funda...

Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) ...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

Reiterates 2008 Annual Financial Guidance DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, tod...

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)

SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment o...

Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells

IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products for cardiac revascularization, today announced a scientific presentation that describes the use of the PHOENIX delivery system combining transmyocardial rev...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

MOUNTAIN VIEW, Calif., June 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today preliminary results from its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. The study did not meet its two prima...

Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that it will host a conference call with simultaneous webcast to discuss the preliminary results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor,...

Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer

- Phase 2 Data To Be Presented Along With Updated Phase 1 Colorectal Cancer Data at ASCO Annual Meeting - SOUTH SAN FRANCISCO, Calif. and CHICAGO, June 1 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology,...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

WOODCLIFF LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that its development partner, Alfacell Corporation (Nasdaq: ACEL ) reported that the preliminary statistical a...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

- Company to Host Conference Call/Webcast at 8:30 a.m. EDT on May 29 - SOMERSET, N.J., May 28 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound,...

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations

COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formul...

Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa

ATLANTA, April 9, 2008 /PRNewswire-USNewswire/ -- Dutch biotechnology company Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) present a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at th...

MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients

Study Continues to Show Lasting Reductions in Mitral Regurgitation Across a Spectrum of Patients CHICAGO, April 1, 2008 /PRNewswire/ -- Percutaneous mitral repair using the MitraClip(R) device may successfully reduce mitral regurgitation (MR) in patients suffering from f...

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies

- Chronic constipation and IBS-C studies each meet primary endpoint - CAMBRIDGE, MASS. and NEW YORK, March 4 /PRNewswire-FirstCall/ -- Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced positive top-line results from two Phase 2b randomized, double-blind, placebo-contr...

NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP

Primary and Secondary Endpoints Do Not Achieve Statistical Significance Company Affirms Plans to File NGX-4010 NDA in 2008 Schedules Investor Conference Call at 5:00 p.m. EST SAN MATEO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmace...

MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity UNION CITY, Calif., Feb. 25 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced p...

A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds

WASHINGTON, Feb. 12 /PRNewswire-USNewswire/ -- A new study demonstrates for the first time that embryonic stem cells can be used to create functional immune system blood cells, a finding which is an important step in the utilization of embryonic stem cells as an alternative source of cells for...

Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients

LONDON, Jan. 16 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic...

Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial

SAN MATEO, Calif., Jan. 15 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary results of a second Phase IIb clinical trial of A-002, for the treatment of cardiovascular disease. In this second study, administration of once-daily A-00...

Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting

Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent Complete Remission Rates Reported ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that preliminary data from its phase II/III randomized stu...

Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting

Company to Hold Conference Call on Monday, December 10, 2007 NEW HAVEN, Conn., Dec. 6 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION ) today announced that preliminary data from its pivotal Phase II trial of Cloretazine(R) (VNP40101M) in elderly patients with de novo...

Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma

Data presented at the 13th Annual Meeting of Connective Tissue Oncology Society held in Seattle, Washington demonstrates clinical activity and tolerability of perifosine as a single agent in patients with chemo-insensitive sarcomas NEW YORK, Nov. 5 /PRNewswire-Firs...

Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference

- Safety and response data from Phase I/II MGCD0103 combination trial with Gemzar(R) in patients with solid tumors presented - - Preliminary evidence of activity in pancreatic cancer - - Phase II portion of the clinical trial in pancreatic cancer patients has ...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

Criteria to Advance SNS-595 to Next Stage of Phase 2 Trial Achieved SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- /ADVANCE FOR RELEASE AT 3:30 P.M. EDT, TODAY/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical-stage biopharmaceutical company developing novel anti...

Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients

Complete Data to be Submitted for Presentation at 2007 San Antonio Breast Cancer Symposium REDWOOD CITY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced encouraging results from a study of Oncotype DX in postmenopausal w...

Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis

Results Show Improvements in RA Signs and Symptoms Compared to Placebo SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical ...